Kesimpta subcutaneous injection 20 mg pen, manufactured by Novartis Pharma (YJ code: 1190405G1024, standard: 20mg 0.4mL 1 kit), contains Ofatumumab. This CD20-directed cytolytic antibody is indicated for the treatment of relapsing forms of multiple sclerosis.
Kesimpta subcutaneous injection 20 mg pen
Need more detailed information?
Contact TASAKI PHARMA for product sourcing, availability, or related support (English support available).